608136-45-4

Upstream product

• 623-33-6 glycine ethyl ester hydrochloride 
• 461694-83-7 (2-amino-6-methoxyphenyl)(phenyl)methanone 

Downstream Products

• 608136-47-6 6-methoxy-2,3-dihydro-2-(dimethylylidenmalonate)-5-phenyl-1H-1,4-benzodiazepine 
• 608136-54-5 6-methoxy-2,3-dihydro-2-(2-hydroxyethyl)-1-methyl-5-phenyl-1H-1,4-benzodiazepine 
• 608136-49-8 (Z)-2,3-dihydro-2-[(methoxycarbonyl)methylen]-6-methoxy-5-phenyl-1H-1,4-benzodiazepine 
• 608136-53-4 (2,3-dihydro-6-methoxy-1-methyl-5-phenyl-1H-1,4-benzodiazepin)-2-acetic acid methyl ester 
• 608136-51-2 (E)-2,3-dihydro-2-[(methoxycarbonyl)methylen]-6-methoxy-1-methyl-5-phenyl-1H-1,4-benzodiazepine 

Relevant academic research and scientific papers

Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as κ-opioid receptor agonists endowed with antinociceptive and antiamnesic activity

The synthesis and biological evaluation of a series of new derivatives of 2-substituted 5-phenyl-1,4-benzodiazepines, structurally related to tifluadom (5), are reported. Chemical and pharmacological studies on compounds 6 have been pursued with the aim o

Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses

The invention concerns the use of PDE2 inhibitors for treating disorders of the central and peripheral nervous system, a method for therapeutic treatment by administering to an animal said inhibitors. More specifically, the invention concerns novel benzodiazepinone derivatives and their uses in therapeutics more particularly for treating pathologies involving activity of a cyclic nucleotide phosphodiesterase type 2. The invention also concerns methods for preparing same and novel synthesis intermediates.